Anti‐VEGF‐A/ANG2 combotherapy limits pathological angiogenesis in the eye: a replication study
Abstract Neovascular and inflammatory retinal diseases including wet age‐related macular degeneration (AMD) can cause severe vision loss among the elderly. Simultaneous neutralization of vascular endothelial growth factor‐A (VEGF‐A) and angiopoietin 2 (ANG2) is envisioned as a novel candidate approa...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2019-04-01
|
| Series: | EMBO Molecular Medicine |
| Online Access: | https://doi.org/10.15252/emmm.201910362 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849761562784432128 |
|---|---|
| author | Anne Wolf Thomas Langmann |
| author_facet | Anne Wolf Thomas Langmann |
| author_sort | Anne Wolf |
| collection | DOAJ |
| description | Abstract Neovascular and inflammatory retinal diseases including wet age‐related macular degeneration (AMD) can cause severe vision loss among the elderly. Simultaneous neutralization of vascular endothelial growth factor‐A (VEGF‐A) and angiopoietin 2 (ANG2) is envisioned as a novel candidate approach to treat wet AMD with better efficacy. However, earlier published data from a genetic mouse model showed data aberrations (Regula et al, 2016). In this issue of EMBO Molecular Medicine, Foxton et al (2019) have provided compelling evidence replicating the data and confirming the overall concept that VEGF‐A/ANG2 combotherapy is effective in suppressing retinal neovascularization. |
| format | Article |
| id | doaj-art-c62dc592d02f47099d46974ded440cfb |
| institution | DOAJ |
| issn | 1757-4676 1757-4684 |
| language | English |
| publishDate | 2019-04-01 |
| publisher | Springer Nature |
| record_format | Article |
| series | EMBO Molecular Medicine |
| spelling | doaj-art-c62dc592d02f47099d46974ded440cfb2025-08-20T03:06:00ZengSpringer NatureEMBO Molecular Medicine1757-46761757-46842019-04-011151210.15252/emmm.201910362Anti‐VEGF‐A/ANG2 combotherapy limits pathological angiogenesis in the eye: a replication studyAnne Wolf0Thomas Langmann1Laboratory for Experimental Immunology of the Eye, Department of Ophthalmology, Faculty of Medicine and University Hospital Cologne, University of CologneLaboratory for Experimental Immunology of the Eye, Department of Ophthalmology, Faculty of Medicine and University Hospital Cologne, University of CologneAbstract Neovascular and inflammatory retinal diseases including wet age‐related macular degeneration (AMD) can cause severe vision loss among the elderly. Simultaneous neutralization of vascular endothelial growth factor‐A (VEGF‐A) and angiopoietin 2 (ANG2) is envisioned as a novel candidate approach to treat wet AMD with better efficacy. However, earlier published data from a genetic mouse model showed data aberrations (Regula et al, 2016). In this issue of EMBO Molecular Medicine, Foxton et al (2019) have provided compelling evidence replicating the data and confirming the overall concept that VEGF‐A/ANG2 combotherapy is effective in suppressing retinal neovascularization.https://doi.org/10.15252/emmm.201910362 |
| spellingShingle | Anne Wolf Thomas Langmann Anti‐VEGF‐A/ANG2 combotherapy limits pathological angiogenesis in the eye: a replication study EMBO Molecular Medicine |
| title | Anti‐VEGF‐A/ANG2 combotherapy limits pathological angiogenesis in the eye: a replication study |
| title_full | Anti‐VEGF‐A/ANG2 combotherapy limits pathological angiogenesis in the eye: a replication study |
| title_fullStr | Anti‐VEGF‐A/ANG2 combotherapy limits pathological angiogenesis in the eye: a replication study |
| title_full_unstemmed | Anti‐VEGF‐A/ANG2 combotherapy limits pathological angiogenesis in the eye: a replication study |
| title_short | Anti‐VEGF‐A/ANG2 combotherapy limits pathological angiogenesis in the eye: a replication study |
| title_sort | anti vegf a ang2 combotherapy limits pathological angiogenesis in the eye a replication study |
| url | https://doi.org/10.15252/emmm.201910362 |
| work_keys_str_mv | AT annewolf antivegfaang2combotherapylimitspathologicalangiogenesisintheeyeareplicationstudy AT thomaslangmann antivegfaang2combotherapylimitspathologicalangiogenesisintheeyeareplicationstudy |